First-in-human phase I trial of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking nanobody, given every 3 weeks (q3w) in patients (pts) with advanced/metastatic solid tumors
| Autor: | Thomas Arnhold, Dooti Roy, Christophe Le Tourneau, Francesco Ricci, Christoph Rummelt, O. Fietz, Rainer Claus, Ralph Fritsch, Zohra Oum'Hamed, Björn Hackanson |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research biology Blocking (radio) business.industry VEGF receptors Angiopoietin 2 First in human Vascular endothelial growth factor 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology Oncology chemistry cardiovascular system Cancer research biology.protein Medicine In patient Signal transduction business hormones hormone substitutes and hormone antagonists |
| Zdroj: | Journal of Clinical Oncology. 36:12024-12024 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2018.36.15_suppl.12024 |
| Popis: | 12024Background: VEGF and Ang-2 inhibitors have demonstrated clinical activity in various tumor types. Given the overlap of the VEGF/VEGFR2 and Ang-2/Tie-2 signaling pathways there is a rationale f... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|